The investigators reported that treatment with darolutamide reduced the risk of radiological progression or death by 49% in ...

Paul E. Dato, MD, discusses how when selecting abiraterone for metastatic hormone-sensitive prostate cancer patients, there are 3 formulations to consider: standard, generic, and micronized versions, ...

The relationship between clinical trial results and real-world experience with enzalutamide and darolutamide shows important patterns: The alignment between trial data and clinical experience supports ...

A panelist discusses how they would communicate these comparative study results to patients by explaining that both enzalutamide and darolutamide effectively control metastatic prostate cancer when ...

Panelists discuss how specific tumor characteristics, such as papillary architecture and presence of carcinoma in situ, guide risk-adapted treatment decisions in non–muscle-invasive bladder cancer.

Panelists discuss how precise risk stratification in non–muscle-invasive bladder cancer enables physicians to tailor treatment and surveillance strategies based on individual patient risk profiles.

The intervention program modestly increased urine production but did not significantly reduce recurrent stone events compared to standard care. Participants in the intervention arm received a "fluid ...

Investigators found that benefits of treatments that are observed in trials also appear in the real world. A recent study examined the relationship between randomized controlled trials and real-world ...

The trial has enrolled 201 patients with localized prostate cancer to date. The TULSA procedure is being compared against radical prostatectomy for localized, intermediate-risk prostate cancer in the ...

Nadofaragene firadenovec elicits high CR rate in phase 3 trial in Japan ...

Nadofaragene firadenovec elicits high CR rate in phase 3 trial in Japan ...

Panelist discusses how benign prostatic hyperplasia (BPH) and its treatments impact men’s sexual health, emphasizing the importance of balancing symptom relief with sexual function preservation, and ...